RAS in FGF23: another piece in the puzzle.
作者信息
Ovejero Diana, Collins Michael T
机构信息
Departament de Medicina (D.O.), Universitat Auto'noma de Barcelona, 08193 Bellaterra, Spain; and Skeletal Clinical Studies Unit (D.O., M.T.C.), Craniofacial and Skeletal Disease Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892-4320.
出版信息
J Clin Endocrinol Metab. 2014 Jan;99(1):63-6. doi: 10.1210/jc.2013-4290.
Abstract
摘要
相似文献
1
RAS in FGF23: another piece in the puzzle.
J Clin Endocrinol Metab. 2014 Jan;99(1):63-6. doi: 10.1210/jc.2013-4290.
2
Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23.
J Clin Endocrinol Metab. 2014 Jan;99(1):E132-6. doi: 10.1210/jc.2013-2813. Epub 2013 Dec 20.
3
Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.
Hum Mol Genet. 2014 Jan 15;23(2):397-407. doi: 10.1093/hmg/ddt429. Epub 2013 Sep 4.
4
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.
J Am Acad Dermatol. 2016 Aug;75(2):420-7. doi: 10.1016/j.jaad.2015.11.012.
5
HRAS mutation mosaicism causing urothelial cancer and epidermal nevus.
N Engl J Med. 2011 Nov 17;365(20):1940-2. doi: 10.1056/NEJMc1109381.
6
[Neurocutaneous melanosis and multiple congenital melanocytic naevi are associated with post-zygotic N-ras mutations].
Ann Dermatol Venereol. 2014 Apr;141(4):314-5. doi: 10.1016/j.annder.2013.12.006. Epub 2014 Jan 14.
7
Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome.
Genes Chromosomes Cancer. 2022 Dec;61(12):740-746. doi: 10.1002/gcc.23092. Epub 2022 Sep 19.
8
N-Ras mutation in vemurafenib-associated expanding melanocytic nevus.
J Dermatol. 2017 May;44(5):e101-e102. doi: 10.1111/1346-8138.13670. Epub 2016 Oct 28.
9
Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment.
Osteoporos Int. 2016 Dec;27(12):3615-3626. doi: 10.1007/s00198-016-3702-8. Epub 2016 Aug 6.
10
Inheritance of giant pigmented hairy nevus of the scalp.
Am J Med Genet. 1981;9(2):177-8. doi: 10.1002/ajmg.1320090213.
引用本文的文献
1
Preoperative evaluation and orthopedic surgical strategies for tumor-induced osteomalacia.
J Bone Oncol. 2024 Mar 28;45:100600. doi: 10.1016/j.jbo.2024.100600. eCollection 2024 Apr.
本文引用的文献
1
Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23.
J Clin Endocrinol Metab. 2014 Jan;99(1):E132-6. doi: 10.1210/jc.2013-2813. Epub 2013 Dec 20.
2
Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.
Hum Mol Genet. 2014 Jan 15;23(2):397-407. doi: 10.1093/hmg/ddt429. Epub 2013 Sep 4.
3
Fibroblast growth factor 23: state of the field and future directions.
Trends Endocrinol Metab. 2012 Dec;23(12):610-8. doi: 10.1016/j.tem.2012.07.002. Epub 2012 Aug 24.
4
Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.
Nat Genet. 2012 Jun 10;44(7):783-7. doi: 10.1038/ng.2316.
5
Mechanism of FGF23 processing in fibrous dysplasia.
J Bone Miner Res. 2012 May;27(5):1132-41. doi: 10.1002/jbmr.1546.
6
Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.
Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):E1146-55. doi: 10.1073/pnas.1110905108. Epub 2011 Oct 17.
7
Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.
J Clin Endocrinol Metab. 2011 Nov;96(11):3541-9. doi: 10.1210/jc.2011-1239. Epub 2011 Aug 31.
8
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
Kidney Int. 2011 Jun;79(12):1370-8. doi: 10.1038/ki.2011.47. Epub 2011 Mar 9.
9
Hyperactive Ras in developmental disorders and cancer.
Nat Rev Cancer. 2007 Apr;7(4):295-308. doi: 10.1038/nrc2109.
10
Klotho converts canonical FGF receptor into a specific receptor for FGF23.
Nature. 2006 Dec 7;444(7120):770-4. doi: 10.1038/nature05315. Epub 2006 Oct 29.
Zotero 插件